Skip Navigation
Skip to contents

ICDM 2018

Research group and committee session

Diabetes together with NAFLD :
Translational understanding for NAFLD in T2DM
16:00~17:30 / Thursday 11 October
Convention Hall B 4F
Chairman: Chul-Hee Kim, Dae Ho Lee
Overview

Organizer: KDA research group on fatty liver disease

This session entitled with 'diabetes together with NAFLD' is translational session and designed to provide a place for clinicians and basic researchers to understand the novel pathophysiologies and potential therapeutic areas for NAFLD in patient with diabetes. In this session, a variety of therapeutic targets based on the novel NAFLD pathophysiologies especially in T2DM patients, including autophagy, inflammasone, FXR/PPARa, organokines and important immunologic regulators, will be presented and discussed. This session will be the first step toward better understanding the importance of NAFLD in T2DM.
Hyon-Seung Yi
Chungnam National University, Korea
Hyon-Seung Yi
RG1-1 Growth differentiation factor 15: an important immunometabolic regulator in hepatic inflammation and insulin resistance
Yong Ho Lee
Yonsei University, Korea
Yong Ho Lee
RG1-2 New therapeutic approaches for non-alcoholic steatohepatitis: autophagy and inflammasome
David D. Moore
Baylor University, USA
RG1-3
RG1-3 Nutrient sensing nuclear receptors control liver energy balance
Kyung Mook Choi
Korea University, Korea
Kyung Mook Choi
RG1-4 Organokines and non-alcoholic fatty liver disease (NAFLD)
Clinical trials in Korea:
Noteworthy clinical trials in Korean type 2 diabetes
09:00~10:40 / Friday 12 October
Flamingo
Chairman: Hyuk-Sang Kwon, Moon-Suk Nam
Overview

Organizer: Committee of Clinical Practice Guideline

This session entitled with 'clinical trials in Korea' is clinical session and designed to provide a place for clinicians to understand the noteworthy clinical trials in Korean patients with type 2 diabetes. In this session, results of clinical trials of Korean patients with type 2 diabetes, including degludec, liraglutide, dapagliflozin, evogliptin, and teneligliptin, will be presented and discussed. By understanding the results of clinical studies conducted in Koreans, we will help to understand the characteristics and treatment directions of diabetes in Koreans.
Nan Hee Kim
Korea University, Korea
Sin Gon Kim
RG2-1 Efficacy and safety of lixisenatide in Korean type 2 diabetic patients with basal insulin failure
Min Kyong Moon
Seoul National University, Korea
Min Kyong Moon
RG2-2 Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Korean patients with type 2 diabetes
Sang Youl Rhee
Kyung Hee University, Korea
Sang Youl Rhee
RG2-3 Liraglutide provides similar glycaemic control as glimepiride and reduces body weight and hypoglycaemia events in Asian population with type 2 diabetes: the Korean subgroup analysis
Kyu Yeon Hur
Sungkyunkwan University, Korea
RG2-4
RG2-4 Efficacy and safety of dapagliflozin in Korean patients with type 2 diabetes
Eun Seok Kang
Yonsei University, Korea
Eun Seok Kang
RG2-5 Teneligliptin clinical trial in Korea
Jung Hyun Noh
Inje University, Korea
Jung Hyun Noh
RG2-6 Efficacy and safety of evogliptin in Korean patients with type 2 diabetes
Seung-Hyun Ko
The Catholic University of Korea, Korea
Seung-Hyun Ko
RG2-7 Summary
Diabetes in Asia :
Sharing real experience of diabetes epidemiologic research
16:20~18:00 / Friday 12 October
Convention hall C
Chairman: Takashi Kadowaki, Doo-Man Kim
Overview

Organizer: Committee of International Liaison

This session entitled with 'Diabetes in Asia' is a clinical session and designed to make an international occasion for gathering of Asian experts (clinicians and epidemiologic researchers) in diabetes care. The representatives participating speakers and panels from more than 10 countries from all over the Asia will present and discuss their experience in diabetes prevention, perspectives and their healthcare system. The ultimate goal of this session resides in continuous collaboration and friendship among the Asian countries and diabetes societies in the prevention and management of diabetes in Asia in the future.
Takashi Kadowaki
University of Tokyo, Japan
Takashi Kadowaki
RG3-1 Effect of an intensified multifactorial intervention on cardiovascular and renal outcomes and mortality in type 2 diabetes (J-DOIT3)
Ronald C.W. Ma
Chinese University of Hong Kong, Hong Kong
RG3-2
RG3-2 Developmental origins of T2DM: a perspective from China
Dae Jung Kim
Ajou University, Korea
Dae Jung Kim
RG3-3 Diabetes epidemic and diabetes care system in Korea
Panel Discussion
Touch Khun (Preah Kossamak Hospital, Cambodia)
Altaisaikhan Khasag (Mongolian National University, Mongolia)
Ikram Shah Ismail (University of Malaya, Malaysia)
Wannee Nitiyanant (Mahidol University, Thailand)
Alimov Anvar Valievich (Ministry of Health, Uzbekistan)
Diabetes guideline :
Diabetes guidelines in perspectives of Asian diabetes phenotype
09:00~11:00 / Saturday 13 October
Emerald Hall B
Chairman: Hyun Shik Son, Young Sik Choi
Overview

Organizer: Committee of Clinical Practice Guideline

This session entitled with 'diabetes guidelines' is clinical session and designed to provide a place for clinicians to understand the cardiovascular risk factor targets in Asian patient with diabetes. In this session, optimal blood pressure goals, LDL cholesterol management (moderate vs. high intensity statin) and glycemic control goals (HbA1c <6.5% vs. <7%) in Asian diabetes will be presented and discussed. This session will provide updated cardiovascular risk factor targets in diabetes.
Mee Kyoung Kim
The Catholic University of Korea, Korea
RG4-1
RG4-1 Optimal BP control target in Asian diabetes; the lower, the better?
Hiroshi Itoh
Keio University, Japan
TBD
RG4-2 LDL-C management in Asian diabetes; moderate vs. high intensity statin - a lesson from EMPATHY study
Dae Jung Kim
Ajou University, Korea
TBD
RG4-3 Glycemic control target in Asian diabetes: HbA1c < 6.5% vs. < 7%?
Panel Discussion
Sang Yong Kim(Chosun University, Korea)
Bo Yeon Kim (Sooncheonhyang University, Korea)
Eun-Jung Rhee(Sungkyunkwan University, Korea)
Diabetes drug, approval, insurance :
Solutions to differences in diabetes drug aproval and insurance standards
09:00~11:00 /
Saturday 13 October Flamingo
Chairman: Tae Sun Park, Seok O Park
Overview

Organizer: Committee of the health insurance and legislation session

Diabetes drugs, which have annual sales of KRW 1 trillion, are different in their efficacy and indications. However, the range of coverage varies even for each series and each individual component, so the conflicts and burdens of prescribing physicians and patients are continuing. Based on the evidence and guidelines, we will discuss how to apply the principles of insurance standard setting to the development of effectiveness and safety verification and policy considerations for diabetics in Korea.
Mijeong Koo
Ministry of Health and Welfare, Korea
RG5-1
RG5-1 Principles of setting up drug insurance standards, focusing on diabetes drugs
Woo Je Lee
University of Ulsan, Korea
RG5-2
RG5-2 Proposal for the principle of insurance application of anti-diabetic drugs
Panel Discussion
RG5-Panel1 Gi Hyeon Seo(HIRA, Korea)
RG5-Panel2 Kyeong Hye Park(National Health Insurance Ilsan Hospital, Korea)
RG5-Panel3 Ministry of Food and Drug Safety